rather than PTCA. Mean time to revascularisation was under 1
hour in the trial, and quite how much later such benefit might
extend is unclear. Care should include vigorous medical
stabilisation in all such patients with thrombolysis, inotropes,
balloon pumping and even ventilation if necessary with a view to
late revascularisation (PTCA or CABG). In young patients early
(<48 hours) revascularisation should be considered.
RReeffeerreenncceess
1 Walters MI, Burn S, Houghton T et al. Cardiogenic shock: are HEROICS
justified? Circulation 1997; 9966 ((ssuuppppll II)): 168A.
2 O’Neil WW. Angioplasty therapy for cardiogenic shock: are
randomised trials necessary? J Am Coll Cardiol1992; 1199 : 915–17.
3 Bolooki H. Emergency cardiac procedures in patients in cardiogenic
shock due to complications of coronary artery disease. Circulation
1989; 7799 ((ssuuppppll II)): I137–48.
4 Norell MS. Randomised trials in cardiogenic shock: what’s the
problem? Eur Heart J1999; 2200 : 987–8.
5 Hochman J, Boland J, Sleeper L et al. Early revascularisation in acute
myocardial infarction complicated by cardiogenic shock. N Engl J Med
1999; 334411 : 625–34.